The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Angiotensin‐converting enzyme inhibitors: Medicinal chemistry and biological actions
Abstract
A decade of experimentation, with work in the last four years greatly accelerated by the availability of captopril, favors the conclusion that angiotensin-converting enzyme inhibitors exert their antihypertensive effect by blocking the formation of angiotensin II. The apparently anomalous efficacy of ACE inhibitors in hypertension characterized by low circulating renin levels may point to the importance of the vascular renin-angiotensin system in controlling blood pressure. Neither kinin potentiation nor blockade of the CNS renin-angiotensin system appear to play a significant role in the antihypertensive effect of captopril. Pharmacological and clinical studies on ACE inhibitors of novel chemical structure will establish their utility as antihypertensive agents and may lead to greater understanding of the mechanism of action of all ACE inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Cited by
Structural basis of the action of thermolysin and related zinc peptidases
Matthews, B. W. (1988) · Accounts of Chemical Research · doi:10.1021/ar00153a003 · Cited by 687
Bioactive peptides derived from bovine whey proteins
Pihlanto-Leppälä, A. (2000) · Trends in Food Science & Technology · doi:10.1016/s0924-2244(01)00003-6 · Cited by 605
Bioactive Peptides in Milk and Dairy Products: A Review
Park, Y. W., & Nam, M. S. (2015) · Korean Journal for Food Science of Animal Resources · doi:10.5851/kosfa.2015.35.6.831 · Cited by 365
Whey as a source of peptides with remarkable biological activities
Brandelli, A., Daroit, D. J., & Corrêa, A. P. F. (2015) · Food Research International · doi:10.1016/j.foodres.2015.01.016 · Cited by 362
Cyclopropane Derivatives and their Diverse Biological Activities
Salaün, J. (2000) · Topics in Current Chemistry · doi:10.1007/3-540-48255-5_1 · Cited by 361
Fluoro ketone inhibitors of hydrolytic enzymes
Gelb, M. H., Svaren, J. P., & Abeles, R. H. (1985) · Biochemistry · doi:10.1021/bi00329a001 · Cited by 343
Bioactive peptides of animal origin: a review
Bhat, Z. F., Kumar, S., & Bhat, H. F. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-015-1731-5 · Cited by 308
“This enzyme regulates extracellular fluid volume and arterial vasoconstriction either by converting angiotensin I to the vasoconstrictor angiotensin II or by inactivating the bradykinin (a vasodilatory peptide) and enkephalins (Petrillo and Ondetti 1982).”
BackgroundMinervini, F., Algaron, F., Rizzello, C. G., Fox, P. F., Monnet, V., & Gobbetti, M. (2003) · Applied and Environmental Microbiology · doi:10.1128/aem.69.9.5297-5305.2003 · Cited by 270
Angiotensin I-converting-enzyme-inhibitory and antimicrobial bioactive peptides.
Gobbetti, M., Minervini, F., & Rizzello, C. G. (2004) · International Journal of Dairy Technology · doi:10.1111/j.1471-0307.2004.00139.x · Cited by 268
Strategy and Tactics in Combinatorial Organic Synthesis. Applications to Drug Discovery
Gordon, E. M., Gallop, M. A., & Patel, D. V. (1996) · Accounts of Chemical Research · doi:10.1021/ar950170u · Cited by 268
Phosphonamidates as transition-state analog inhibitors of thermolysin
Bartlett, P. A., & Marlowe, C. K. (1983) · Biochemistry · doi:10.1021/bi00289a002 · Cited by 265
Recent developments in the design of angiotensin‐converting enzyme inhibitors
Wyvratt, M. J., & Patchett, A. A. (1985) · Medicinal Research Reviews · doi:10.1002/med.2610050405 · Cited by 253
Metadata
- Authors
- Petrillo, E. W., & Ondetti, M. A.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 1982-01
- Volume
- 2
- Issue
- 1
- Pages
- 1-41
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2002602770
- Cited by
- 192
- References
- 1
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.